The inherent difference in intracellular glucose-6-phosphatase levels, as it relates to benign cells and tumor cells, can be used to support the notion that the delayed phase and dual-time-point diagnostic 18F-FDG PET/CT imaging approaches are advantageous [36,100,111,154,159,170-176]. This evidence concerns the gene G6PC1 and neoplasm.